The Week in Review: September 22 – September 29, 2017

Friday, September 29, 2017 News Recap: Merck discontinues HCV programs. There were rumours, but now it’s official: Merck has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. In a statement the company said the decision was made based on a review of available Pha...

Pacific AIDS Network signs HCV Manifesto, signaling its commitment to greater involvement of persons with hepatitis C in its organization

Pacific AIDS Network (PAN) recently became the fifteenth (15th) organization to sign the HCV Manifesto ( . This document, more than simply a list of “rights” transforms the principles developed by persons with HIV/AIDS: GIPA/MIPA (Greater and more Meaningful Involvement of Persons with AIDS in their own care, in the governance of organizations which speak for and support them, and in the broader society as well), and “Nothing